Skip to main content
Top
Published in: Cancer Immunology, Immunotherapy 6/2023

Open Access 30-11-2022 | Research

Different effects of NK cells and NK-derived soluble factors on cell lines derived from primary or metastatic pancreatic cancers

Authors: Piera Filomena Fiore, Anna Laura Di Pace, Libenzio Adrian Conti, Nicola Tumino, Francesca Besi, Silvia Scaglione, Enrico Munari, Lorenzo Moretta, Paola Vacca

Published in: Cancer Immunology, Immunotherapy | Issue 6/2023

Login to get access

Abstract

Natural killer (NK) cells are cytotoxic lymphoid cells that play a key role in defenses against tumors. However, their function may be severely impaired in patients with pancreatic adenocarcinoma (PA). Indeed, PA cells release soluble factors, thereby generating an immunosuppressive environment that dysregulates NK-cell cytolytic function and favors tumor immune evasion. Here, we analyzed the interactions between NK and PA cells using the PANC-1 and CAPAN-1 cell lines derived from a ductal PA and metastatic lesion, respectively. Metastatic and nonmetastatic cell lines were both able to impair NK cytolytic activity. An analysis of the effect of NK cells and NK-cell-derived exosomes revealed substantial differences between the two cell lines. Thus, NK cells displayed higher cytotoxicity against nonmetastatic PA cells than metastatic PA cells in both 2D cultures and in a 3D extracellular matrix cell system. In addition, NK-derived exosomes could penetrate only PANC-1 spheroids and induce cell killing. Remarkably, when PANC-1 cells were exposed to NK-derived soluble factors, they displayed substantial changes in the expression of genes involved in epithelial-to-mesenchymal transition (EMT) and acquired resistance to NK-mediated cytolysis. These results, together with their correlation with poor clinical outcomes in PA patients, suggest that the induction of resistance to cytolysis upon exposure to NK-derived soluble factors could reflect the occurrence of EMT in tumor cells. Our data indicate that a deeper investigation of the interaction between NK cells and tumor cells may be crucial for immunotherapy, possibly improving the outcome of PA treatment by targeting critical steps of NK-tumor cell crosstalk.
Appendix
Available only for authorised users
Literature
22.
go back to reference Oppenheim DE, Roberts SJ, Clarke SL, Filler R, Lewis JM, Tigelaar RE et al (2005) Sustained localized expression of ligand for the activating Nkg2d receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance. Nat Immunol 6(9):928–937. https://doi.org/10.1038/ni1239CrossRefPubMed Oppenheim DE, Roberts SJ, Clarke SL, Filler R, Lewis JM, Tigelaar RE et al (2005) Sustained localized expression of ligand for the activating Nkg2d receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance. Nat Immunol 6(9):928–937. https://​doi.​org/​10.​1038/​ni1239CrossRefPubMed
28.
go back to reference Supino R, Rodolfo M, Mariani M, Mapelli E (1992) Heterogeneity and phenotypic instability of chemotherapeutic and immunologic sensitivity in murine and human melanoma cell clones. Tumori J 78(1):5–9CrossRef Supino R, Rodolfo M, Mariani M, Mapelli E (1992) Heterogeneity and phenotypic instability of chemotherapeutic and immunologic sensitivity in murine and human melanoma cell clones. Tumori J 78(1):5–9CrossRef
Metadata
Title
Different effects of NK cells and NK-derived soluble factors on cell lines derived from primary or metastatic pancreatic cancers
Authors
Piera Filomena Fiore
Anna Laura Di Pace
Libenzio Adrian Conti
Nicola Tumino
Francesca Besi
Silvia Scaglione
Enrico Munari
Lorenzo Moretta
Paola Vacca
Publication date
30-11-2022
Publisher
Springer Berlin Heidelberg
Published in
Cancer Immunology, Immunotherapy / Issue 6/2023
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-022-03340-z

Other articles of this Issue 6/2023

Cancer Immunology, Immunotherapy 6/2023 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine